Last reviewed · How we verify
TAFASITAMAB
TAFASITAMAB is a drug. It is currently FDA-approved (first approved 2020).
Tafasitamab is a treatment used for relapsed or refractory Diffuse Large B Cell Lymphoma (DLBCL), a type of Non-Hodgkin Lymphoma. It is often combined with lenalidomide as part of the treatment regimen.
At a glance
| Generic name | TAFASITAMAB |
|---|---|
| Modality | Monoclonal antibody |
| Phase | FDA-approved |
| First approval | 2020 |
Approved indications
Common side effects
- Neutropenia
- Fatigue
- Anemia
- Diarrhea
- Thrombocytopenia
- Cough
- Pyrexia
- Peripheral edema
- Respiratory tract infection
- Decreased appetite
Serious adverse events
- Infections
- Pneumonia
- Febrile neutropenia
- Cerebrovascular accident
- Respiratory failure
- Progressive multifocal leukoencephalopathy
- Sudden death
Key clinical trials
- Study to Assess the Safety and Tolerability of Tafasitamab in Adult Participants With Primary Autoimmune Blood Cell Disorders (PHASE2)
- A Phase II Trial of Mosunetuzumab, Polatuzumab, Tafasitamab, and Lenalidomide in Patients With Relapsed B-cell NHL (PHASE2)
- Chemotherapy (DA-EPOCH+/-R) and Targeted Therapy (Tafasitamab) for the Treatment of Newly-Diagnosed Philadelphia Chromosome Negative B Acute Lymphoblastic Leukemia (PHASE2)
- A Study of Epcoritamab With Lenalidomide and Tafasitamab in People With Diffuse Large B Cell Lymphoma (PHASE2)
- Phase I/II Trial of ONC-PluReceptor NK Cells With Epcoritamab and Tafasitamab for Patients With Recurrent or Refractory B-cell Non-Hodgkin Lymphoma (PHASE1, PHASE2)
- A Safety and Preliminary Efficacy Study of CC-99282, Alone and in Combination With Anti-lymphoma Agents in Participants With Relapsed or Refractory Non-Hodgkin Lymphomas (R/R NHL) (PHASE1, PHASE2)
- Tafasitamab and Rituximab for Front-Line Treatment of Post-Transplant Lymphoproliferative Disorder (PHASE2)
- Tafasitamab (MOR00208) in Pediatric Patients With Relapsed or Refractory Acute B Lineage Leukemia (PHASE1, PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| FDA label | Mechanism, indications, dosing, boxed warnings, drug interactions |
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- TAFASITAMAB CI brief — competitive landscape report
- TAFASITAMAB updates RSS · CI watch RSS
Frequently asked questions about TAFASITAMAB
What is TAFASITAMAB?
TAFASITAMAB is a Monoclonal antibody drug.
When was TAFASITAMAB approved?
TAFASITAMAB was first approved on 2020.
What development phase is TAFASITAMAB in?
TAFASITAMAB is FDA-approved (marketed).
What are the side effects of TAFASITAMAB?
Common side effects of TAFASITAMAB include Neutropenia, Fatigue, Anemia, Diarrhea, Thrombocytopenia, Cough. Serious adverse events: Infections, Pneumonia, Febrile neutropenia, Cerebrovascular accident.
Related
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing